Homepage Featured News
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
Guardant Health, Inc. today announced data showing its blood-based multimodal test achieved clinically significant thresholds of sensitivity and specificity in detecting colorectal cancer (CRC).
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting
New data demonstrating the ability of the company’s investigational next-generation Guardant SHIELD™ multi-cancer assay to accurately detect early-stage cancers.
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
A partnership with Epic, the nation’s most widely used comprehensive health record, to integrate the company’s broad portfolio of cancer tests with Epic.
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
Guardant Health provided the following statement regarding a lawsuit filed by Illumina that seeks to challenge Guardant Health’s ownership and authorship of a portion of its intellectual property and to suppress competition in the market.
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
Guardant Health, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling, in patients with advanced solid tumors.
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Research Annual Meeting
Guardant Health, Inc. announced it will present new data from its broad portfolio of blood tests at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022.
Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for Guardant360 TissueNext™ under the existing local coverage determination (LCD) (MolDX: Next-Generation Sequencing for Solid Tumors).
Close the Gap: Disparities in Cancer Screening Threaten Lives
February marks National Cancer Prevention Month, an initiative to bring awareness to ways Americans can reduce their risk for cancer. While more than 1.7 million Americans will be diagnosed with cancer this year, research suggests that up to 50 percent of cases – and 50 percent of deaths – are preventable. That’s why one key recommendation is to get regular cancer screenings.
Guardant Health Statement on Biden-Harris Administration’s Renewed Commitment to the Cancer Moonshot
Guardant Health stands with the Biden-Harris Administration’s renewed commitment to the Cancer Moonshot